Back Lau, J, Bloch, K, Schffer, L, et al (24 Sept 2015) 'Discovery of the once-weekly glucagon-like peptide-1 (glp-1) analogue Semaglutide', Journal Medicinal Chemistry , 58/18
2023: Lawsuits initiated against Novo Nordisk by patients who developed gastroparesis
age 18 years
Patients were offered escalating doses of semaglutide (0.25, 0.5, 1.0, 1.25, 1.5 and 2.0 mg depending on tolerance and affordability) and dosing was assessed at 3 monthly intervals
The body needs protein to fuel some parts of itself
[8] [9] Rates were generally higher in obesity trials (SURMOUNT), with nausea affecting up to 43% of patients at the highest doses